You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 3,973,000


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 3,973,000
Title: Process for purified rabies vaccine
Abstract:An improved purified rabies vaccine is produced by high-centrifugal force centrifugation of the crude egg-embryo-derived vaccine, redispersion of the separated solids, centrifugation of that dispersion at low centrifugal force, and collecting the supernatant.
Inventor(s): Lavender; John F. (Indianapolis, IN)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Application Number:05/597,054
Patent Claims:1. A method of purifying an egg-embryo-derived crude rabies vaccine which consists of:

A. separating the crude vaccine into liquid and solid phases by centrifuging the crude vaccine at from about 30,000 to about 80,000 G. for from about 15 to about 45 minutes;

B. collecting and dispersing the solid phase in a physiologically-acceptable vaccine diluent to produce a suspension;

C. separating the suspension into liquid and solid phases by centrifuging the suspension at from about 500 to about 2,500 G. for from about 2 to about 10 minutes; and

D. collecting the liquid phase.

2. A method of claim 1 which consists of:

A. centrifugation at from about 45,000 to about 65,000 G. for from about 20 to about 40 minutes;

B. collecting and dispersing the solid phase in a physiologically-acceptable vaccine diluent to produce a suspension;

C. centrifugation at from about 1,000 to about 2,000 G. for from about 4 to about 8 minutes; and

D. collecting the liquid phase.

3. A purified egg-embryo-derived rabies vaccine, prepared by the following process:

A. infecting embryonated duck eggs with rabies virus;

B. incubating the eggs at about 36.degree.C. for about 14 days;

C. harvesting the embryos from the infected eggs;

D. grinding and dispersing the embryos in a quantity of a physiologically-acceptable vaccine diluent which provides a final dispersed volume of the egg-embryo-derived crude rabies vaccine which does not exceed 1 ml. per 200 mg. of embryos dispersed therein;

E. removing gross amounts of tissue by straining or centrifuging;

F. purifying the crude rabies vaccine by the method of claim 1; and

G. inactivating the vaccine, which inactivation may take place either before or after purifying the vaccine;

each milliliter of which purified rabies vaccine represents at least 200 mg. of embryos, and which vaccine contains less than about 15 mg. of lipids per g. of embryos represented by the vaccine and also contains less than about 2 mg. of protein nitrogen per g. of embryos represented by the vaccine.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.